PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Urologix Inc ( ) from 1996 to May 15 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Urologix stock (ULGX) PE ratio as of May 15 2024 is 0. More Details

Urologix Inc (ULGX) PE Ratio (TTM) Chart

To

Urologix Inc (ULGX) PE Ratio (TTM) Historical Data

Total 0
  • 1
Urologix PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data

Urologix Inc (ULGX) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Urologix Inc is a United States-based company engaged in the development, manufacturing, and marketing of minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The firm markets the Cooled ThermoTherapy (CTC) product line and the Prostiva Radio Frequency (RF) Therapy System (Prostiva). The CTC produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. The CTC product line includes the CoolWave and Targis Control Units and the CTC Advance catheter.